Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis

Abstract

The aim of the present study was to investigate the expression of the transcription factor Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α in the tumor tissue of patients with invasive ductal carcinoma(IDC); in addition, we examined correlations between these markers. Two hundred and sixteen IDC patients, who were not previously been treated with chemo-or radiotherapy, were included in the study. All tumors were grade I-III. Expression of molecular markers was determined by immunohistochemical analysis on paraffin-embedded tissue sections. Follow-up data were collected for 3 months to 10 years and analyzed for tumor recurrence, survival time, and prognostic risk factors. We determined Ki-67 expression correlates with the expression of ER, PR, HER-2, EGFR, and TOP-α, as well as lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in IDC. Positive Ki-67 expression was a risk factor for rapid tumor recurrence and may help tumor progression, leading to poor prognosis in IDC. Ki-67 was directly correlated with EGFR, TOP II-α, lymph node involvement, high tumor grade, lymphovascular invasion, high tumor stage, and high TNM stage in the hormone receptor subtypes of breast cancer. In triple negative breast cancer, Ki-67 correlated with TOP II-α. Expression of Ki-67 correlated with that of ER, PR, HER-2, EGFR, TOP II-α, and p21. In addition, the biomarker Ki-67 has a role as a prognostic factor and indicates a poor prognosis in IDC.

Luminal B is the Most Common Intrinsic Molecular Subtypes of Invasive Ductal Breast Carcinoma Patients in East Kalimantan, Indonesia

“…Furthermore, Luminal B has an aggressive phenotype and worse prognosis compared to luminal A. It is characterized by higher levels of growth factor receptor such as HER2, which activates signaling pathways (Yan et al, 2015). In details, HER2+ subtypes have a poor prognosis, and characterized by high proliferation rates.…”

Relationship between erb-B2 mRNA Expression in Blood and Tissue of Invasive Ductal Carcinoma Breast Cancer Patients and Clinicopathological Characteristics of the Tumors

“…Because of gene-expression-based subtype classification systems (Zhao et al, 2015) and various therapeutic responses or disease outcome that can be affected by means of different types of tumors (Yan et al, 2015), in the present study, 50 BC patients were divided into 4 groups: A (ER and/or PR positive and HER-2 negative), B (HR positive and HER-2 positive), C (HR negative and HER-2 positive) and D (HR negative and HER-2 negative) according to hormone receptor and HER-2 status. We compared the erb-B2 expression in peripheral blood and tumor tissue between different groups.…”

“…Reliable detection of erb-B2 overexpression (amplification of erb-B2 gene or overexpression of the protein) is important because of its role in therapeutic approach. In addition to early detection, research about tumor molecular profiles can be improved patient prognosis and care (Yan et al, 2015).…”

Histopathological Characteristics: Clinical Course of Breast Cancer Subtypes Depending on the ER(+) (−)/PR(+) (−) Receptor Status

“…With luminal B tumors, insensitivity to endocrine treatment is also higher than with HR+/HER2−, while chemotherapy resistance is more frequent than with TN and HER2+ tumors [8]. Invasion into the lymph nodes is also more common in luminal B tumors compared to that in luminal A [11,12].…”